WALVAX: Net profit in the first quarter increased by 4082.41% year-on-year
I'm LongbridgeAI, I can summarize articles.WALVAX achieved operating revenue of 444 million yuan in the first quarter of 2026, a year-on-year decrease of 3.98%; net profit was 111 million yuan, a year-on-year increase of 4082.41%. The performance change was mainly due to changes in the accounting estimates for expected credit losses on accounts receivable, leading to a decrease in the amount of bad debt provisions, as well as a reduction in research and development expenses
On April 27th, WALVAX (300142.SZ) announced that it achieved an operating income of 444 million yuan in the first quarter of 2026, a year-on-year decrease of 3.98%; the net profit attributable to shareholders of the listed company was 111 million yuan, a year-on-year increase of 4082.41%. The performance change was mainly due to the company's adjustment of the expected credit loss accounting estimates for accounts receivable based on industry conditions and actual business situations, leading to a decrease in the provision for bad debts of accounts receivable, as well as the reversal of bad debt provisions during the period; at the same time, the company's 20-valent pneumococcal polysaccharide conjugate vaccine (core stock) and the mRNA vaccine project for novel coronavirus variants have reached the capitalization stage, while the same period last year was in the expense stage, resulting in a decrease in research and development expenses.
More exclusive planning and expert columns in the stock channel, free to check>>